Atossa Genetics Ownership
| ATOS Stock | USD 4.19 0.02 0.48% |
Shares in Circulation | First Issued 2009-09-30 | Previous Quarter 8.6 M | Current Value 8.6 M | Avarage Shares Outstanding 4.6 M | Quarterly Volatility 15.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atossa Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. Atossa Stock Ownership Analysis
About 21.0% of the company shares are held by institutions such as insurance companies. The book value of Atossa Genetics was presently reported as 5.78. The company recorded a loss per share of 3.45. Atossa Genetics last dividend was issued on the 20th of April 2018. The entity had 1:15 split on the 2nd of February 2026. Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Atossa Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. For more info on Atossa Genetics please contact FCAP MD at 206 588 0256 or go to https://www.atossatherapeutics.com.Besides selling stocks to institutional investors, Atossa Genetics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Atossa Genetics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Atossa Genetics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Atossa Genetics Quarterly Liabilities And Stockholders Equity |
|
Atossa Genetics Insider Trades History
Less than 1% of Atossa Genetics are currently held by insiders. Unlike Atossa Genetics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Atossa Genetics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Atossa Genetics' insider trades
Atossa Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Atossa Genetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atossa Genetics backward and forwards among themselves. Atossa Genetics' institutional investor refers to the entity that pools money to purchase Atossa Genetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2025-06-30 | 335 K | Susquehanna International Group, Llp | 2025-06-30 | 273.9 K | Northern Trust Corp | 2025-06-30 | 263.4 K | Connor Clark & Lunn Inv Mgmt Ltd | 2025-06-30 | 198.7 K | Squarepoint Ops Llc | 2025-06-30 | 181.1 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 160.9 K | Aster Capital Management (difc) Ltd | 2025-06-30 | 144.9 K | Jain Global Llc | 2025-06-30 | 123.1 K | Bank Of America Corp | 2025-06-30 | 99.6 K | Vanguard Group Inc | 2025-06-30 | 5.8 M | Ameriprise Financial Inc | 2025-06-30 | 3 M |
Atossa Genetics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atossa Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atossa Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atossa Genetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Atossa Genetics Outstanding Bonds
Atossa Genetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Atossa Genetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Atossa bonds can be classified according to their maturity, which is the date when Atossa Genetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.